How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/semi-synthetic-penicillin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Semi-Synthetic Penicillin — Competitive Intelligence Brief

Semi-Synthetic Penicillin (Semi-Synthetic Penicillin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic (semi-synthetic penicillin). Area: Infectious Disease.

marketed Beta-lactam antibiotic (semi-synthetic penicillin) Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Semi-Synthetic Penicillin (Semi-Synthetic Penicillin) — Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Semi-synthetic penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Semi-Synthetic Penicillin TARGET	Semi-Synthetic Penicillin	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	marketed	Beta-lactam antibiotic (semi-synthetic penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Nafcillin (or equivalent)	Nafcillin (or equivalent)	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	Beta-lactam antibiotic (semi-synthetic penicillin)	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic (semi-synthetic penicillin) class)

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Semi-Synthetic Penicillin — Competitive Intelligence Brief. https://druglandscape.com/ci/semi-synthetic-penicillin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab